| Literature DB >> 35751068 |
Erika Alejandra Cifuentes1, Maria A Sierra1,2, Andrés Felipe Yepes3, Ana Margarita Baldión3, José Antonio Rojas4, Carlos Arturo Álvarez-Moreno4, Juan Manuel Anzola1,5, María Mercedes Zambrano1,5, Monica G Huertas6,7.
Abstract
BACKGROUND: Studies of the respiratory tract microbiome primarily focus on airway and lung microbial diversity, but it is still unclear how these microbial communities may be affected by intubation and long periods in intensive care units (ICU), an aspect that today could aid in the understanding of COVID19 progression and disease severity. This study aimed to explore and characterize the endotracheal tube (ETT) microbiome by analyzing ETT-associated microbial communities.Entities:
Keywords: Endotracheal tubes; Intensive care units (ICUs); Microbial diversity; Respiratory tract microbiome; Ventilator-associated pneumonia
Mesh:
Substances:
Year: 2022 PMID: 35751068 PMCID: PMC9233342 DOI: 10.1186/s12931-022-02086-7
Source DB: PubMed Journal: Respir Res ISSN: 1465-9921
Fig. 1Sampling strategy. ETT samples were collected and used for both analysis of microbial communities by sequencing of the 16S rRNA gene and for culturing in laboratory media. A section of the endotracheal tube was cut and immediately placed in 0.85% NaCl. Associated bacteria were dislodged by three cycles of vortex followed by sonication. DNA was extracted and the V3-V4 hypervariable region of the 16S rRNA gene was amplified and sequenced on the Illumina MiSeq platform
Fig. 2Alpha diversity comparisons. Violin plots showing community alpha diversity according to hospital (a) and extubation reason (b). Statistical differences based on ICU were assessed with Welch t-test (Shannon: p = < 0.001, Chao1: p = 0.0056, Simpson p = 0.001, OTUs observed: p = 0.0010), and with One-way ANOVA for extubation reason (Shannon: p = < 0.0305, Chao1: p = 0.0343, Simpson p = 0.0278, OTU number: p = 0.0215. c Intubation (top) and patient age (bottom) were tested for correlation using Spearman’s rank correlation coefficient (rho). Statistical differences were observed only for intubation days (Shannon: p = < 0.001, Chao1: p = 0.0001, Simpson p = 0.0009, OTUs observed: p = 1.391e−05)
Demographics and characteristics of the patients
| Location | |||
|---|---|---|---|
| ICU-1 (n = 73) | ICU-2 (n = 42) | ||
| Age | |||
| Mean ± SD | 64 ± 14 | 67 ± 18,87 | |
| Intubation days | |||
| Median (quartile 1, quartile 3) | 6 (4, 10) | 4.5 (3, 8) | |
| Sex | n (%) | n (%) | |
| Male | 43 (58.9) | 19 (45.2) | |
| Female | 30 (41.0) | 23 (54.7) | |
| Population characteristics | |||
| Oncological background | 22 (30.1) | 7 (16.66) | |
| Transplant | 2 (2.73) | 1 (2.38) | |
| Use of steroids | 5 (6.84) | 4 (9.52) | |
| Previous hospital stay | 40 (54.7) | 17 (40.47) | |
| VAP | 18 (24.6) | 5 (11.90) | |
| Extubation reason | |||
| Recovery | 28 (38.35) | 28 (66.66) | |
| Death | 36 (49.31) | 6 (14.28) | |
| Tracheostomy | 9 (12.32) | 8 (19.04) | |
| Intubation length of stay (grouped by days) | |||
| Long (> 16 days) | 6 (8.22) | 0 (0) | |
| Middle (6–15 days) | 31 (42.46) | 17 (40.47) | |
| Short (0–5 days) | 36 (49.31) | 25 (59.52) | |
| Hospital antibiotic use | p value* | ||
| Previous antibiotic use | 45 (61.64) | 16 (38.09) | 0.024 |
| Antibiotic during intubation time | 63 (86.30) | 29 (69.04) | 0.047 |
| Use of beta-lactams | 58 (79.45) | 22 (52.38) | < 0.001 |
| Use of glycopeptides | 11 (15.06) | 7 (16.66) | 0.80 |
Data is shown as number of patients and percentage. *Chi square test
Fig. 3Sampling site defines composition. a PCoA axis 1:2 and 2:3 based on the Bray–Curtis index shows that patient microbiomes differ according to the hospital. Clusters were shown to be significant (p = 0.00199) calculated with ADONIS. b Heatmap of the 13 OTUs with significant differences in abundance found by ALDEx2
Biofilm producing isolates of the ESKAPE group in VAP patients
| Bacteria | Number of isolates | Biofilm producing isolates |
|---|---|---|
| 1 | 0 | |
| 1 | 0 | |
| 3 | 1 | |
| 4 | 4 | |
| 5 | 3 |
Results obtained from culture isolation and identification via 16S rDNA sequencing for patients with VAP
| Sample ID | Isolates | High-throughput sequencing of 16S rDNA* |
|---|---|---|
| 8-F | No growth | |
| 74-C | ||
| 72-C | ||
| 64-C | ||
| 60-C | ||
| 54-C | ||
| 52-C | ||
| 48-C | No growth | |
| 33-C | ||
| 10-F | ||
| 11-C | ||
| 15-F | ||
| 19-C | ||
| 19-F | ||
| 1-C | ||
| 20-C | ||
| 24-C | ||
| 24-F | ||
| 25-C | ||
| 30-C | ||
Five most abundant OTUs. Samples labeled with letter C belongs to ICU-1, samples labeled with letter F belongs to ICU-2